[go: up one dir, main page]

AUPS271902A0 - Gene expression and multiple sclerosis - Google Patents

Gene expression and multiple sclerosis

Info

Publication number
AUPS271902A0
AUPS271902A0 AUPS2719A AUPS271902A AUPS271902A0 AU PS271902 A0 AUPS271902 A0 AU PS271902A0 AU PS2719 A AUPS2719 A AU PS2719A AU PS271902 A AUPS271902 A AU PS271902A AU PS271902 A0 AUPS271902 A0 AU PS271902A0
Authority
AU
Australia
Prior art keywords
gene expression
multiple sclerosis
sclerosis
gene
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPS2719A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Griffith University
Original Assignee
Griffith University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Griffith University filed Critical Griffith University
Priority to AUPS2719A priority Critical patent/AUPS271902A0/en
Publication of AUPS271902A0 publication Critical patent/AUPS271902A0/en
Priority to AU2003229114A priority patent/AU2003229114A1/en
Priority to PCT/AU2003/000684 priority patent/WO2003102227A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/285Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AUPS2719A 2002-05-31 2002-05-31 Gene expression and multiple sclerosis Abandoned AUPS271902A0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AUPS2719A AUPS271902A0 (en) 2002-05-31 2002-05-31 Gene expression and multiple sclerosis
AU2003229114A AU2003229114A1 (en) 2002-05-31 2003-06-02 Gene expression and multiple sclerosis
PCT/AU2003/000684 WO2003102227A1 (en) 2002-05-31 2003-06-02 Gene expression and multiple sclerosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPS2719A AUPS271902A0 (en) 2002-05-31 2002-05-31 Gene expression and multiple sclerosis

Publications (1)

Publication Number Publication Date
AUPS271902A0 true AUPS271902A0 (en) 2002-06-20

Family

ID=3836282

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPS2719A Abandoned AUPS271902A0 (en) 2002-05-31 2002-05-31 Gene expression and multiple sclerosis

Country Status (2)

Country Link
AU (1) AUPS271902A0 (en)
WO (1) WO2003102227A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2414775A1 (en) 2000-05-03 2001-11-08 Expressive Constructs, Inc. A method and device for improving protein stability and solubility
EP1624886A2 (en) * 2003-05-12 2006-02-15 Expressive Constructs, Inc. Methods for increasing cell and tissue viability
WO2006097463A2 (en) * 2005-03-15 2006-09-21 Ares Trading S.A. Compositions and methods for treating and diagnosing inflammatory disorders
WO2007071437A2 (en) * 2005-12-22 2007-06-28 Ares Trading S.A. Compositions and methods for treating inflammatory disorders
EP2121971B1 (en) * 2006-12-29 2011-03-30 Tel HaShomer Medical Research Infrastructure and Services Ltd. Methods and kits for diagnosis of multiple sclerosis in probable multiple sclerosis subjects
CA2706849A1 (en) * 2007-11-28 2009-06-04 Redoxis Aktiebolag New treatment of autoimmune conditions
JP5833924B2 (en) 2008-09-19 2015-12-16 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション Methods for identification and prediction of multiple sclerosis and therapeutic response

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69737815T2 (en) * 1996-01-30 2008-03-06 The Scripps Research Institute, La Jolla G-PROTEIN COUPLED RECEPTOR WITH ENLARGED, EXTRA-CELLULAR DOMAIN
US5834238A (en) * 1997-04-08 1998-11-10 Incyte Pharmaceuticals, Inc. Human GTP binding protein
US6190909B1 (en) * 1997-04-17 2001-02-20 Millennium Pharmaceuticals, Inc. TH2-specific gene
US5874248A (en) * 1997-08-21 1999-02-23 Incyte Pharmaceuticals, Inc. Glutathione S-transferase homolog
US5919627A (en) * 1997-10-29 1999-07-06 Incyte Pharmaceuticals, Inc. Microsomal glutathione-S-transferase
US6030809A (en) * 1997-11-25 2000-02-29 Incyte Pharmaceuticals, Inc. Glutathione S-transferase
US5945306A (en) * 1997-12-16 1999-08-31 Incyte Pharmaceuticals, Inc. Ras protein
AU2982799A (en) * 1998-03-03 1999-09-20 Zymogenetics Inc. Human semaphorin zsmf-7
US6660476B2 (en) * 2000-05-02 2003-12-09 City Of Hope Polymorphisms in the PNMT gene
WO2002048326A2 (en) * 2000-12-14 2002-06-20 Bayer Aktiengesellschaft Human caplain proteins and polynucleotides coding therefor
CA2479780A1 (en) * 2001-04-04 2002-10-17 Universite De Montreal Antisense calpain nucleotides and uses thereof

Also Published As

Publication number Publication date
WO2003102227A1 (en) 2003-12-11

Similar Documents

Publication Publication Date Title
AU2002234755A1 (en) Interferon-alpha induced gene
AU2003267036A1 (en) Tubulysin biosynthesis gene
AU2003211367A1 (en) Novel dehydrogenase and gene encoding the same
AUPS271902A0 (en) Gene expression and multiple sclerosis
AU2003231827A1 (en) Pseudo-tissues and uses thereof
AU2003302173A1 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
AU2003295311A1 (en) Caterpiller gene family
AU2003239589A1 (en) Eta-1 gene and methods for use
AU2003294705A1 (en) NtSM GENE
AU2002953015A0 (en) Modified lacz gene
AU2003229114A1 (en) Gene expression and multiple sclerosis
AU2003267790A1 (en) Lipase inhibitors and uses thereof
AUPR295001A0 (en) A gene and uses therefor
AU2003228397A1 (en) HAUSP-p53 INTERACTION AND USES THEREOF
AU2003297297A1 (en) Elf3 gene compositions and methods
AU2003292721A1 (en) Novel protein and its gene
AU2003252991A1 (en) INTERFERON-Alpha INDUCED GENE
AU2003216442A1 (en) Enkurin and uses thereof
AU2003267384A1 (en) Bhyd gene
AU2002310591A1 (en) Interferon-alpha induced gene
AU2003284640A1 (en) Type 2 diabetes-associated gene
AU2003220853A1 (en) Abc transporter-associated gene abcc13
AUPR513701A0 (en) A gene and uses therefor
AU2003203240A1 (en) Novel phospholipase a2 and gene thereof
AUPS079702A0 (en) Genetic sequence and uses therefor